• Channels
    • All News
    • Premium Stories
    • R&D
    • Pharma
    • Venture
    • People
    • Startups
    • Regulatory
    • Deals
    • IPOs
    • China
    • Cell/Gene Tx
    • Bioregnum
    • Peer Review
    • Discovery
    • Outsourcing
    • AI
    • Special
  • Events
  • Biopharma Jobs
  • More
    • Webinars
    • Sponsored Posts
    • Biotech Voices
    • Advertise
    • Privacy Policy
    • About Us
    • Help
  • SUBSCRIBE

The top 10 pipeline blowups, set­backs and sna­fus for H1 2019

4 months ago
R&D

Ver­tex's Resh­ma Ke­wal­ra­mani takes CEO post as long­time vet Jeff Lei­den moves to new role

4 months ago
R&D

Bris­tol-My­ers does it again, dis­ap­point­ing in­vestors with a sur­prise Op­di­vo PhI­II fail­ure as chemo com­bo flops

4 months ago
Pharma
R&D

GSK culls more res­pi­ra­to­ry drugs out of PhII as fo­cus shifts to can­cer

4 months ago
R&D

Cel­gene re­struc­tures a big Jounce pact, ze­ro­ing in on new I/O path­way with $530M deal — and bump­ing ICOS

4 months ago
Deals

Stay tuned: Bio­gen’s num­bers are great — it’s their wor­ri­some fu­ture that leaves an­a­lysts skit­tish

4 months ago
R&D

3 years af­ter the FDA forced Chi­as­ma back in­to PhI­II, they’re back with pos­i­tive da­ta — but now they have a ri­val

4 months ago
R&D

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

4 months ago
Pharma
R&D

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

4 months ago
People
R&D

Cel­gene racks up third Ote­zla ap­proval, heat­ing up talks about who Bris­tol-My­ers will sell to

4 months ago
Deals
Pharma

In an­oth­er dis­ap­point­ment for in­vestors, FDA slaps down Bio­haven’s re­vised ver­sion of an old ALS drug

4 months ago
R&D

On a hot streak, No­var­tis ex­ecs run the odds on their two most im­por­tant PhI­II read­outs. Which is 0.01% more like­ly to suc­ceed?

4 months ago
R&D

Medicxi is rolling out its biggest fund ever to back Eu­rope's top 'sci­en­tists with strange ideas'

4 months ago
Venture

Af­ter a decade, Vi­iV CSO John Pot­tage says it's time to step down — and he's hand­ing the job to long­time col­league Kim Smith

4 months ago
People
R&D

On a glob­al romp, Boehringer BD team picks up its third R&D al­liance for Ju­ly — this time fo­cused on IPF with $50M up­front

4 months ago
Deals

Backed by some of the biggest names in biotech, Nor­bert Bischof­berg­er gets his megaround for plat­form tech out of MIT

4 months ago
Startups
Venture

With loom­ing ‘apoc­a­lypse of drug re­sis­tance,’ Mer­ck’s com­bi­na­tion an­tibi­ot­ic scores FDA ap­proval on two fronts

4 months ago
Regulatory

The $1.1M good­bye: Gilead CSO John McHutchi­son is out as Daniel O’Day shakes up the se­nior team

4 months ago
People

Go­ing in­side cells, Sung Joo Lee has sketched some big goals for his small — but glob­al — team of drug hunters

4 months ago
R&D
Startups

Astel­las buys in­to Fre­quen­cy's re­gen­er­a­tive med strat­e­gy with a $625M al­liance on hear­ing loss

4 months ago
Deals

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al boom­towns — start­ing with Boston

4 months ago
People
Venture

Takeda's trans­la­tion­al cell ther­a­py group revs up for a race to the clin­ic with off-the-shelf CAR-T

4 months ago
Cell/Gene Tx
People

Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

4 months ago
Deals

Ab­b­Vie beefs up the on­col­o­gy pipeline, bag­ging an up­start STING play­er with its own unique ap­proach

4 months ago
Deals
First page Previous page 11121314151617 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Stories
  • Don't Miss

Channels

  • R&D
  • Pharma
  • Venture
  • People
  • Startups
  • Regulatory
  • Deals
  • IPOs
  • China
  • Cell/Gene Tx
  • Bioregnum
  • Peer Review
  • Discovery
  • Outsourcing
  • AI
  • Special

More

  • Events
  • Webinars
  • Sponsored Posts
  • Biotech Voices
  • Advertise
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© 2019 — Endpoints Company

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Sign in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you sign in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS by John Carroll & team — all the news at 11:30a ET

EARLY EDITIONby Arsalan Arif — skimmable links and news at 7:15a ET